Storia in 4 fonti

Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win

Outlook Therapeutics has notched a win in its uphill battle to commercialize an ophthalmic version of Roche’s Avastin (bevacizumab) in the U.S., with the FDA now agreeing that the drug has demonstr | After a formal dispute resolution process that followed three prior rejections, the FDA has decided that Outlook's eye drug candidate Lytenava has shown evidence of effectiveness.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

fiercepharma.comStai leggendo3 mesi fa

Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win

originale

Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win

Confronto fonti

Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win

Timeline cronologica

Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA - Outlook Therapeutics (NASDAQ:OTLK)

Three CRLs later, Outlook says FDA will sign off on its version of Avastin for wet AMD

Three CRLs later, Outlook says FDA will sign off on its version of Avastin for wet AMD

Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA - Outlook Therapeutics (NASDAQ:OTLK)

FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote

FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote

Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win

Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal